You are here

  • Home
  • Archive
  • Volume 14, Issue e1
  • Personalised treatment plan for children and adolescents with advanced haematological malignancies: a response to paediatric relapsed acute leukaemia: curative intent chemotherapy improves quality of life

Article Text

Article menu
Download PDFPDF
Letter
Personalised treatment plan for children and adolescents with advanced haematological malignancies: a response to paediatric relapsed acute leukaemia: curative intent chemotherapy improves quality of life
  1. Gabriel Revon-Rivière1,2,
  2. Arthur Sterin1 and
  3. Paul Saultier1
  1. 1 Pediatric Oncology and Hematology, Hôpital de la Timone, Marseille, Provence-Alpes-Côte d'Azur, France
  2. 2 Pediatric Palliative Care Team, Hôpital de la Timone, Marseille, Provence-Alpes-Côte d'Azur, France
  1. Correspondence to Dr Gabriel Revon-Rivière, Pediatric Oncology and Hematology, Hôpital de la Timone, 13005 Marseille, Provence-Alpes-Côte d'Azur, France; gabriel.revon-riviere{at}ap-hm.fr

https://doi.org/10.1136/bmjspcare-2021-003140

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Research focusing on quality of life (QoL) in children and adolescents with high-risk malignancy (HRM) is of primary importance. As most of these patients are treated in low-income and middle-income countries,1 publications from Central America are of great value. We are thankful to Salaverria et al. for their work addressing this complex and key subject.2

    Patients with HRM were defined by Mahmood et al. as having >50% risk of death due to their disease. These patients should receive optimal symptom management and optimal disease-directed therapies to increase both their survival and QoL. To achieve …

    View Full Text

    Footnotes

    • Contributors All authors contributed equally to drafting and revising manuscript.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; internally peer reviewed.